Adenosine Receptor Antagonist

Adenosine Receptor Antagonists (99):

Cat. No.	Product Name	Effect	Purity

HY-19533

SCH 58261	Antagonist	99.71%
SCH 58261 is a potent, selective and competitive antagonist of adenosine A2A receptor with an IC₅₀ of 15 nM, and displays 323-, 53- and 100-fold more selective for A2A receptor than A1, A2B, and A3 receptors, respectively.

HY-10888

Istradefylline	Antagonist	99.70%
Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with K_i of 2.2 nM in experimental models of Parkinson's disease.

HY-100937

DPCPX	Antagonist	99.02%
DPCPX (PD 116948), a xanthine derivative, is a highly potent and selective Adenosine A1 receptor antagonist, with a K_i of 0.46 nM in ³H-CHA binding to A1 receptors in rat whole brain membranes.

HY-121453R

Bamifylline (hydrochloride) (Standard)	Antagonist
Bamifylline (hydrochloride) (Standard) is the analytical standard of Bamifylline (hydrochloride). This product is intended for research and analytical applications. Bamifylline hydrochloride is a drug in the chemical class of xanthine that acts as a selective adenosine A1 receptor antagonist.

HY-163701

hA2AAR antagonist 1	Antagonist
hA2AAR antagonist 1 (compound 4a) is a highly selective hA2AAR antagonist with a K_i of 5 nM. hA2AAR antagonist 1 can be used in the study of immune-oncology.

HY-129393

Etrumadenant	Antagonist	99.76%
Etrumadenant (AB928) is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. Etrumadenant relieves adenosine-mediated immune suppression. Etrumadenant has immunomodulatory and antitumor activities.

HY-101978

Ciforadenant	Antagonist	99.85%
Ciforadenant (CPI-444) is a potent, orally active and selective adenosine A2A receptor (A2AR) antagonist, which induces antitumor responses.

HY-103166

PSB-603	Antagonist	≥99.0%
PSB-603 is a potent and highly selective A_2B adenosine receptor antagonist exhibiting a K_i value of 0.553 nM and virtually no affinity for the human and rat A₁ and A_2A and the human A₃ receptors up to a concentration of 10 μM.

HY-101980

Imaradenant	Antagonist	99.68%
AZD4635 (HTL1071) is a potent, selective and orally active adenosine A2A receptor (A2AR) antagonist. AZD4635 binds to human A2AR with a K_i of 1.7 nM and shows >30-fold selectivity over other adenosine receptors.

HY-14121

MRS 1754	Antagonist	98.31%
MRS 1754 is a selective antagonist radioligand for A_2B adenosine receptor with very low affinity for A₁ and A₃ receptors of both humans and rats.

HY-103169

SCH442416	Antagonist	99.68%
SCH442416 is a potent, selective and brain-penetrant antagonist of adenosine A_2A receptor (A_2AR), with K_is of 0.048 and 0.5 nM for human and rat A_2AR respectively. SCH442416 displays more than 23000-fold selectivity over A₁R, A_2BR, and A₃R (K_i=1111, 10000, and 10000 nM, respectively). SCH442416 can be used for imaging of adenosine A_2A receptors in rat and primate brain.

HY-B0140

Aminophylline	Antagonist	99.90%
Aminophylline is a competitive and non-selective phosphodiesterase (PDE) inhibitor. Aminophylline is a competitive adenosine receptor antagonist. Aminophylline has apulmonary vasodilator action as well as a bronchodilator action and has the potential for asthma research.

HY-121119

MRS 1523	Antagonist	99.93%
MRS 1523 is a potent and selective adenosine A₃ receptor antagonist with K_i values of 18.9 nM and 113 nM for human and rat A₃ receptors, respectively. In rat this corresponds to selectivities of 140- and 18-fold vs A₁ and A_2A receptors, respectively. MRS 1523 can exert antihyperalgesic effect through N-type Ca channel block and action potential inhibition in isolated rat dorsal root ganglion (DRG) neurons.

HY-10081

GS-6201	Antagonist	98.47%
GS-6201 (CVT-6883) is a selective adenosine A2B receptor antagonist. GS-6201 displays high affinity and selectivity for the human adenosine A2B receptors (K_i=22 nM). GS-6201 reduces caspase-1 activity in the heart, and attenuates cardiac remodeling after acute myocardial infarction (AMI) in the mouse. GS-62013 attenuates the airway reactivity induced by NECA, AMP, or allergen in sensitized mice.

HY-10889

Preladenant	Antagonist	99.23%
Preladenant is a potent and competitive antagonist of the human adenosine A2A receptor with a K_i of 1.1 nM and has over 1000-fold selectivity over other adenosine receptors.

HY-B0004

Doxofylline	Antagonist	99.65%
Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm.

HY-B0128

Diphylline	Antagonist	99.25%
Diphylline (Diprophylline) is a potent A1/A2 adenosine receptor antagonist and cyclic nucleotide phosphodiesterase inhibitor. Diphylline, a xanthine derivative, is a bronchodilator and vasodilator agent and has the potential for chronic bronchitis and emphysema.

HY-137442

Inupadenant	Antagonist	99.54%
Inupadenant is an orally active, highly selective A_2A receptor antagonist. Inupadenant is not brain-penetrant. Inupadenant has potent anti-tumor activity.

HY-10995

Tozadenant	Antagonist	98.30%
Tozadenant is an adenosine A_2A receptor antagonist, with K_i of 11.5 nM on human A_2A and 6 nM on rhesus A_2A.

HY-10965

Rolofylline	Antagonist	99.45%
Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP₄₅₀). Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases.

Name
Email *

	Sorry, but the email address you supplied was invalid.